• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Clinical and epidemiological links with calcinosis in adult dermatomyositis

byAdam Whittington
June 4, 2014
in Chronic Disease, Dermatology
Reading Time: 2 mins read
dermatomyositis
Share on FacebookShare on Twitter

1. In adults with dermatomyositis (DM), calcinosis was positively associated with longer disease duration, fingertip ulcers, and NXP-2 autoantibodies and was negatively associated with anti-TIF-1-g antibodies.

Evidence Rating Level: 2 (Good)

Study Rundown: DM is an autoimmune disease that occasionally involves calcinosis, a sign that results from calcium deposition in the skin and subcutaneous tissues. Several candidate autoantibodies have been associated with DM, though their relationship with calcinosis is poorly understood. In this study, the authors retrospectively analyzed DM from one referral center with the objective of identifying features that associate with calcinosis. After adjusting for confounding variables, authors identified several risk factors including fingertip ulcers, longer duration of disease, and NXP-2 autoantibodies that positively associated with calcinosis. Conversely, the presence of anti-TIF-1- antibodies were found to be protective. Also, the novel finding that calcinosis frequently co-occurs with fingertip ulcers led the authors to hypothesize that a vasculopathy-type process may be common to both pathogeneses. One of the strengths of this study was its large, well-phenotyped cohort that may be difficult to obtain for rare, complex diseases. A key weakness was a potential sampling bias, as only patients from a single tertiary clinic were studied.

Click to read the study in JAMA Dermatology

Relevant reading: Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?

In-Depth [retrospective cohort]: A total of 126 adult patients from Stanford University Medical Center were screened for a diagnosis of DM from 2006-2013. Of this group, 14 patients (11.1%) were reported to have developed calcinosis. Participants’ medical information was obtained and their plasma was screened for DM-specific and DM-associated autoantibodies using various protein assays. The data were evaluated using univariate and multivariate models and were adjusted for potential confounders. When compared to DM patients without calcinosis, analyses suggested that individuals with calcinosis had longer median disease duration (6.9 years [2.4-18.1] vs. 3.9[0.2-19.2]; p=.003), had more fingertip ulcers (50.0% vs. 9.3%, p<0.001), were more likely to have autoantibodies against NXP-2 (OR, 15.52; 95% CI, 2.0-119.9, p=.009), and were less likely to have anti-TIF-1-g antibodies (OR, 0.2; 95% CI, 0.01-0.99; p=.04). Other antibodies (anti-MDA-5 and anti-Ro-52) were initially identified as positive associations with calcinosis; however, the association wasn’t persistent after separate multivariate models for each antibody were examined.

RELATED REPORTS

Brepocitinib becomes first oral therapy approved for adult dermatomyositis

2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome

Dazukibart is effective in reducing disease activity in adults with refractory dermatomyositis

Image: CC/Wiki

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: dermatomyositis
Previous Post

Azithromycin linked with decreased mortality in elderly pneumonia patients

Next Post

Smaller changes in kidney filtration may predict end stage renal disease progression

RelatedReports

Chronic Disease

Brepocitinib becomes first oral therapy approved for adult dermatomyositis

September 18, 2026
Pharma Roundup

2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome

September 15, 2026
dermatomyositis
Chronic Disease

Dazukibart is effective in reducing disease activity in adults with refractory dermatomyositis

February 12, 2025
#VisualAbstract: Intravenous immune globulin improved disease severity in dermatomyositis
StudyGraphics

#VisualAbstract: Intravenous immune globulin improved disease severity in dermatomyositis

May 2, 2023
Next Post
Urinary mRNA profiling accurately diagnoses rejection in kidney allografts

Smaller changes in kidney filtration may predict end stage renal disease progression

Diffusion tensor imaging valuable in the evaluation of peripheral neuropathy

Schizophrenia linked with higher rates of violence, suicide, and early mortality

Weekly dalbavancin noninferior to daily therapy for acute skin infection [DISCOVER 1 and 2 Trials]

Weekly dalbavancin noninferior to daily therapy for acute skin infection [DISCOVER 1 and 2 Trials]

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality
  • Alcohol use declines but remains above pre-pandemic levels
  • High maternal egg-peanut intake not associated with reduced infant allergy
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.